iPSC-Derived Cardiomyocytes: Advancing Cardiac Research & Drug Discovery

iPSC-Derived Cardiomyocytes: Advancing Cardiac Research and Drug Discovery Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have revolutionized cardiac research, drug discovery, and regenerative medicine since their introduction by Takahashi and Yamanaka in 2006. This review explores the current state of hiPSC-CM technology, its applications, and future directions, with a focus on the contributions of companies like NEXEL in advancing this field. Generating hiPSC-Derived Cardiomyocytes: Techniques and Characterization hiPSC-CMs are generated through directed differentiation protocols that mimic embryonic cardiac development. These protocols typically involve modulation of Wnt signalling pathways and use of growth factors such as activin A and BMP4. The resulting cardiomyocytes express cardiac-specific markers like troponin T (cTnT) and -actinin and exhibit spontaneous beating. NEXEL, has developed proprietary protocols for efficient generation of high-quality hiPSC-CMs. Their Cardiosight -S product line offers highly pure and electrophysiologically active cardiomyocytes suitable for various experimental applications. hiPSC-CMs in Drug Discovery: Revolutionizing Toxicity Screening One of the most significant applications of hiPSC-CMs is in drug discovery and cardiotoxicity screening. These cells provide a human-relevant model for assessing the effects of novel compounds on cardiac function, potentially reducing the reliance on animal models and improving the translation of preclinical findings to clinical outcomes. hiPSC-CMs have been successfully used to detect drug-induced arrhythmias and contractile dysfunction. Studies have shown that hiPSC-CMs can accurately predict the cardiotoxicity of drugs that were withdrawn from the market due to safety concerns. Modeling Cardiac Diseases with hiPSC-CMs: Insights and Innovations hiPSC-CMs derived from patients with genetic cardiac disorders offer unique opportunities for studying disease mechanisms and developing personalized therapies. Researchers have successfully modelled various cardiac diseases using hiPSC-CMs, including: Long QT syndrome Hypertrophic cardiomyopathy Dilated cardiomyopathy NEXEL's Cardiosight -S platform has been instrumental in facilitating disease modelling studies, providing researchers with consistent and reliable cellular models for investigating cardiac pathologies. Overcoming Challenges in hiPSC-CM Development: Limitations and Solutions Despite their potential, hiPSC-CMs face several challenges that limit their widespread adoption. A major limitation is their immature phenotype compared to adult cardiomyocytes. hiPSC-CMs typically exhibit fetal-like electrophysiological properties, metabolic profiles, and structural organization. Efforts to enhance maturation include: Prolonged culture Electrical and mechanical stimulation 3D culture systems NEXEL and other companies are actively developing advanced culture methods to produce more mature and physiologically relevant hiPSC-CMs. Future Directions for hiPSC-CMs: Advancements and Emerging Technologies The field of hiPSC-CM research is rapidly evolving, with several exciting developments on the horizon: Improved Maturation Protocols Researchers are exploring novel approaches to enhance the maturity of hiPSC-CMs, including the use of small molecules and gene editing techniques. These advancements aim to create more adult-like cardiomyocytes that better recapitulate the physiology of the human heart. Organ-on-a-Chip Technologies Integration of hiPSC-CMs into microfluidic devices promises to create more complex and physiologically relevant cardiac models. These systems can incorporate multiple cell types and provide a more accurate representation of the in vivo cardiac environment, enhancing their utility in drug screening and disease modelling. Regenerative Medicine Applications Ongoing clinical trials are investigating the potential of hiPSC-CMs for cardiac repair following myocardial infarction. While challenges remain, such as cell retention and integration, the ability to generate patient-specific cardiomyocytes holds great promise for personalized regenerative therapies. Multi-Cell Type Models Incorporation of other cardiac cell types, such as fibroblasts and endothelial cells, to create more comprehensive in vitro cardiac tissues is an active area of research. These complex models aim to better replicate the cellular interactions and tissue architecture of the native heart, providing more accurate platforms for drug testing and disease modelling. NEXEL's Impact on hiPSC-CM Research: Current Role and Future Prospects NEXEL's contributions to the field of hiPSC-CMs exemplify the crucial role of biotechnology companies in advancing scientific research and clinical applications. By providing high-quality, standardized hiPSC-CMs through their Cardiosight -S platform, NEXEL enables researchers to conduct more reproducible and translatable studies. As the field progresses, collaborations between academic institutions and companies like NEXEL will be essential in addressing the current limitations of hiPSC-CMs and realizing their full potential in drug discovery, disease modelling, and regenerative medicine. The continued development of more mature and functionally relevant hiPSC-CMs, coupled with advanced culturing and analysis techniques, promises to further establish these cells as indispensable tools in cardiac research and therapeutic development.   References: Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. Burnett SD, Blanchette AD, Chiu WA . Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization. Expert Opin Drug Metab Toxicol. 2021;17(8):973-988. Burnett SD, Blanchette AD, Grimm FA, et al . Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019;381:114711. Blinova K, Dang Q, Millard D, et al . International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018;24(13):3582-3592. Itzhaki I, Maizels L, Huber I, et al . Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225-229. Lan F, Lee AS, Liang P, et al . Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101-113. Sun N, Yazawa M, Liu J, et al . Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4(130):130ra47. Karbassi E, Fenix A, Marchiano S, et al . Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 2020;17(6):341-359. Ronaldson-Bouchard K, Ma SP, Yeager K, et al . Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556(7700):239-243. Funakoshi S, Fernandes I, Mastikhina O, et al . Enhanced maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. Mol Ther. 2021;29(4):1395-1410. Zhao Y, Rafatian N, Feric NT, et al . A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling. Cell. 2019;176(4):913-927.e18. Menasch P, Vanneaux V, Hag ge A, et al . Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015;36(30):2011-2017. Giacomelli E, Bellin M, Sala L, et al . Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 2017;144(6):1008-1017.